THE USE OF MALONONITRILE IN THE TREATMENT OF MENTAL ILLNESSES
Abstract
Malononitrile administered intravenously in doses varying from 2-4 mgms/kg body weight was of no benefit in the treatment of 9 patients who received approximately the amount of malononitrile recommended by Hydén and Hartelius. With the exception of a mild toxic reaction after injections the patients displayed no improvement of their psychotic conditions. In addition, no alterations were observed in their emotional reactions. Our investigations were carried out predominantly on schizophrenic patients. The material on manic-depressives is insufficient from which to draw conclusions. The theoretic concept of Caspersson and Hydén concerning the relationship of nucleoprotein metabolism and malononitrile was not investigated at this time. We were interested in the clinical application of malononitrile which, as our reported findings show, is essentially negative.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
